Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19.
作者信息
Nainu Firzan, Mamada Sukamto S, Emran Talha B
机构信息
Department of Pharmacy, Faculty of Pharmacy, Hasanuddin University, Makassar, Indonesia.
Department of Pharmacy, BGC Trust University Bangladesh, Chittagong.
出版信息
Int J Surg. 2023 Feb 1;109(2):109-111. doi: 10.1097/JS9.0000000000000101.
Abstract
摘要
相似文献
1
Prospective role of NSAIDs with antiviral properties for pharmacological management of postsurgical procedures during COVID-19.具有抗病毒特性的非甾体抗炎药在新冠疫情期间术后处理的药理学管理中的前瞻性作用。
Int J Surg. 2023 Feb 1;109(2):109-111. doi: 10.1097/JS9.0000000000000101.
2
Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19.新型冠状病毒主蛋白酶抑制剂和花生四烯酸途径调节剂：非甾体类抗炎药治疗 COVID-19。
Comput Biol Med. 2021 Sep;136:104686. doi: 10.1016/j.compbiomed.2021.104686. Epub 2021 Jul 29.
3
Strategies Tackling Viral Replication and Inflammatory Pathways as Early Pharmacological Treatment for SARS-CoV-2 Infection: Any Potential Role for Ketoprofen Lysine Salt?针对 SARS-CoV-2 感染的病毒复制和炎症途径的早期药物治疗策略：酮咯酸赖氨酸盐有何潜在作用？
Molecules. 2022 Dec 15;27(24):8919. doi: 10.3390/molecules27248919.
4
Further data on use of NSAIDs for the home-care therapy of COVID-19.关于非甾体抗炎药用于COVID-19家庭护理治疗的更多数据。
Intern Emerg Med. 2023 Aug;18(5):1599-1602. doi: 10.1007/s11739-023-03272-1. Epub 2023 Apr 12.
5
The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19.在 COVID-19 中使用非甾体抗炎药（NSAIDs）。
NPJ Prim Care Respir Med. 2022 Sep 21;32(1):35. doi: 10.1038/s41533-022-00300-z.
6
Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.家庭作为治疗 COVID-19 的新前沿：抗炎药物的案例。
Lancet Infect Dis. 2023 Jan;23(1):e22-e33. doi: 10.1016/S1473-3099(22)00433-9. Epub 2022 Aug 26.
7
NSAIDs and COVID-19: A Systematic Review and Meta-analysis.非甾体抗炎药（NSAIDs）与 COVID-19：系统评价和荟萃分析。
Drug Saf. 2021 Sep;44(9):929-938. doi: 10.1007/s40264-021-01089-5. Epub 2021 Aug 2.
8
Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19.非甾体抗炎药和其他类二十烷酸途径修饰剂对抗病毒和过敏反应的影响：COVID-19 期间欧洲变应性反应和临床免疫学会类二十烷酸共识报告工作组
Allergy. 2022 Aug;77(8):2337-2354. doi: 10.1111/all.15258. Epub 2022 Feb 25.
9
Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo .2019冠状病毒病期间的非甾体抗炎治疗：是友是敌？对乔洛的《2019冠状病毒病（COVID-19）与非甾体抗炎药（NSAID）》的回应
Ann Rheum Dis. 2021 Feb;80(2):e13. doi: 10.1136/annrheumdis-2020-217638. Epub 2020 Apr 30.
10
RAASI, NSAIDs, antidiabetics, and anticoagulants: More data needed to be labeled as harmful or neutral in SARS-CoV-2 infection.肾素-血管紧张素-醛固酮系统抑制剂（RAASI）、非甾体抗炎药（NSAIDs）、抗糖尿病药物和抗凝剂：在新型冠状病毒肺炎（SARS-CoV-2）感染中，需要更多数据才能将其标记为有害或中性。
Proc Natl Acad Sci U S A. 2021 May 18;118(20). doi: 10.1073/pnas.2025609118.
引用本文的文献
1
Consensus on the Use of Mefenamic Acid in Pediatric Practice (MAPP): Perspectives From Indian Pediatricians.小儿科使用甲芬那酸的共识（MAPP）：印度儿科医生的观点
Cureus. 2025 Jul 21;17(7):e88412. doi: 10.7759/cureus.88412. eCollection 2025 Jul.
2
Effectiveness of paracetamol-NSAID combinations for upper and lower respiratory tract infections: a preliminary evaluation in primary care.对乙酰氨基酚与非甾体抗炎药联合用药治疗上、下呼吸道感染的有效性：基层医疗中的初步评估
Eur J Clin Pharmacol. 2024 May;80(5):781-783. doi: 10.1007/s00228-024-03651-3. Epub 2024 Feb 17.
3
Evaluating NSAIDs in SARS-CoV-2: Immunomodulatory mechanisms and future therapeutic strategies.评估非甾体抗炎药在2019冠状病毒病中的作用：免疫调节机制与未来治疗策略
Heliyon. 2024 Feb 2;10(3):e25734. doi: 10.1016/j.heliyon.2024.e25734. eCollection 2024 Feb 15.
Zotero 插件